Intellia Therapeutics Inc (NASDAQ: NTLA) on Friday, soared 9.45% from the previous trading day, before settling in for the closing price of $6.77. Within the past 52 weeks, NTLA’s price has moved between $5.90 and $28.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 15.68% annually for the last half of the decade. The company achieved an average annual earnings per share of 11.04%. With a float of $97.42 million, this company’s outstanding shares have now reached $102.03 million.
In an organization with 403 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 91.17%, operating margin of -923.1%, and the pretax margin is -896.77%.
Intellia Therapeutics Inc (NTLA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 5.89%, while institutional ownership is 90.20%. The most recent insider transaction that took place on Mar 04 ’25, was worth 6,104. In this transaction EVP, Chief Technical Officer of this company sold 679 shares at a rate of $8.99, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, General Counsel sold 2,572 for $8.99, making the entire transaction worth $23,122. This insider now owns 111,925 shares in total.
Intellia Therapeutics Inc (NTLA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.29% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 5.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.25, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.40 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Let’s dig in a bit further. During the last 5-days, its volume was 3.97 million. That was better than the volume of 3.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.36%. Additionally, its Average True Range was 0.79.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 14.94%, which indicates a significant decrease from 43.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.45% in the past 14 days, which was higher than the 80.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.26, while its 200-day Moving Average is $16.05. However, in the short run, Intellia Therapeutics Inc’s stock first resistance to watch stands at $7.68. Second resistance stands at $7.96. The third major resistance level sits at $8.47. If the price goes on to break the first support level at $6.89, it is likely to go to the next support level at $6.38. Assuming the price breaks the second support level, the third support level stands at $6.10.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 767.08 million based on 103,517K outstanding shares. Right now, sales total 57,880 K and income totals -519,020 K. The company made 12,870 K in profit during its latest quarter, and -128,900 K in sales during its previous quarter.
